Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Docetaxel 19pembrolizumab 14Surveys and Questionnaires 7Radiotherapy 7Paclitaxel 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Standard of Care 6Specimen Handling 6Radiosurgery 6Psychiatric Rehabilitation 6Early Intervention, Educational 6Trastuzumab 5Nivolumab 5enzalutamide 4Interviews as Topic 4motexafin gadolinium 3cabozantinib 3X-Rays 3Sirolimus 3Methods 3Educational Status 3Cisplatin 3Carboplatin 3Azacitidine 3tisotumab vedotin 2rucaparib 2pertuzumab 2pegilodecakin 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Antibodies × Thoracic × Clear all
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡